VideoRespiDART 2018RV521: A new and potent RSV fusion inhibitor in clinical development | Stuart Cockerill, PhDView Video
VMVeronica MillerPhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Regulatory landscape for NASH | Veronica MillerView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Aramchol for NASH and beyond: From scientific rationale to clinical development | Carol BrosgartView Video
MHEManal Hamdy El-SayedMD, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations | Manal El-Sayed, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017The Re-vival of Bile Acid Based Therapeutics for Children and Adults | Saul KarpenView Video
ASArun SanyalMD, MBBSVideoViral Hepatitis and Liver DiseaseHEP DART 2017NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes | Arun SanyalView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Looking back to move forward: designing next-gen RNAi for best results in HBV | Bruce GivenView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017HEV Update: Diagnostics and Management | Kenneth Sherman, MD, PhDView Video
FZFabien ZoulimMD, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination | Fabien Zoulim, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Update on Merck’s HCV Program | Mike RobertsonView Video
TATarik AsselahMD, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination | Tarik AsselahView Video
JFJordan FeldMD, MPHVideoViral Hepatitis and Liver DiseaseHEP DART 2017DAA Controversies: Do they Cause HBV Reactivation and/or HCC? | Jordan Feld, MD, MPHView Video
